Multidisciplinary management of advanced prostate cancer: Changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials

Urology

Volumn 65, Issue 5 SUPPL., 2005, Pages 18-22

  Carducci, Michael A ^a,c   Carroll, Peter R ^b,d   Smith, Matthew R ^d   DiPaola, Robert S ^d   Nelson, Joel B ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ATRASENTAN; DOCETAXEL; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG TOLERABILITY; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; MEDICAL SPECIALIST; MONOTHERAPY; PATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; SALVAGE THERAPY; SURGEON; AGED; ARTICLE; BLOOD; MALE; ONCOLOGY; PROSTATE TUMOR; UROLOGY;

AGED; ANDROGEN ANTAGONISTS; CLINICAL TRIALS; HUMANS; MALE; MEDICAL ONCOLOGY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; UROLOGY;

EID: 18244410137     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2005.03.044     Document Type: Conference Paper

References (23)

1. M.R. Smith J.B. Nelson Future therapies in hormone-refractory prostate cancer Urology 65 suppl 5A 2005 9 17
2. D.P. Petrylak The current role of chemotherapy in metastatic hormone-refractory prostate cancer Urology 65 suppl 5A 2005 3 8
3. E.J. Small S. Halabi N.A. Dawson Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients a phase III trial (CALGB 9583) J Clin Oncol 22 2004 1025 1033
4. I.F. Tannock R. de Wit W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
5. D.P. Petrylak C.M. Tangen M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
6. J. Lapointe C. Li J.P. Higgins Gene expression profiling identifies clinically relevant subtypes of prostate cancer Proc Natl Acad Sci U S A 101 2004 811 816
7. A. Latil I. Bieche L. Chene Gene expression profiling in clinically localized prostate cancer a four-gene expression model predicts clinical behavior Clin Cancer Res 9 2003 5477 5485
8. G.V. Glinsky A.B. Glinskii A.J. Stephenson Gene expression profiling predicts clinical outcome of prostate cancer J Clin Invest 113 2004 913 923
9. D. Singh P.G. Febbo K. Ross Gene expression correlates of clinical prostate cancer behavior Cancer Cell 1 2002 203 209
10. S. Bettuzzi M. Scaltriti A. Caporali Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data a 5-year follow-up study Cancer Res 63 2003 3469 3472
11. R. Shinghal C. Yemoto J.E. McNeal Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy prostate-specific antigen Urology 61 2003 380 385
12. A.V. D’Amico J.W. Moul P.R. Carroll Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383
13. A.V. D’Amico K. Cote M. Loffredo Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer J Clin Oncol 20 2002 4567 4573
14. A.V. D’Amico M.-H. Chen K.A. Roehl Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125 135
15. A.J. Stephenson S.F. Shariat M.J. Zelefsky Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy JAMA 291 2004 1325 1332
16. D.M. Nudell G.D. Grossfeld V.K. Weinberg Radiotherapy after radical prostatectomy treatment outcomes and failure patterns Urology 54 1999 1049 1057
17. J.A. Kalapurakal C.F. Huang M.M. Neriamparampil Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy Int J Radiat Oncol Biol Phys 54 2002 1047 1054
18. M.J. Shulman E.A. Benaim The natural history of androgen independent prostate cancer J Urol 172 2004 141 145
19. R.S. DiPaola I.M. Thompson National cooperative group trials Urology 65 suppl 5A 2005 23 29
20. F.A. Conde L. Sarna R.K. Oka Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy Urology 64 2004 335 340
21. W.F. Pirl G.I. Siegel M.J. Goode Depression in men receiving androgen deprivation therapy for prostate cancer a pilot study Psychooncology 11 2002 518 523
22. P.J. Shapiro J.C. Coyne L.K. Kruus Interest in services among prostate cancer patients receiving androgen deprivation therapy Psychooncology 13 2004 512 525
23. J.K. Petty J.T. Vetto Beyond doughnuts tumor board recommendations influence patient care J Cancer Educ 17 2002 97 100